why choose us

First received: March 16, 2025

Clinical Trial: Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Neovascular Age-Related Macular Degeneration (nAMD)

Study Type: OBSERVATIONAL


Official Title: Durability of Three Monthly Loading Doses With Faricimab Injections in Patients With Treatment-naïve Neovascular Age-related Macular Degeneration

Brief Summary: Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries.The implementation of anti-VEGF therapies in the last decades has significantly improved AMD management.Faricimab (Vabysmo®), a bispecific antibody targeting both Vascular Endothelial Growth Factor A (VEGF-A) and Angiopoietin-2 (Ang-2), offers enhanced disease control by both inhibiting angiogenesis and stabilizing blood vessels to prevent inflammation and…

Read more